BioSpace News Archive

Bristol-Myers Squibb Company announced that the European Commission has approved Opdivo flat dosing schedule of 240 mg infused over 30 minutes every two weeks or 480 mg infused over 60 minutes every four weeks for the adjuvant treatment of adult patients with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection.

TG Therapeutics, Inc. announced that final long-term results from the Phase 3 GENUINE study demonstrated that ublituximab in combination with ibrutinib improved progression-free survival (PFS), as determined by Independent Review Committee.

Intellia Therapeutics, Inc. (NASDAQ: NTLA), a leading genome editing company focused on the development of curative therapeutics using CRISPR/Cas9 technology is presenting one oral presentation and four poster presentations at the 27th Annual Congress of the European Society of Gene and Cell Therapy (ESGCT) meeting taking place October 22-25, 2019, in Barcelona, Spain.

Sernova Corp. (TSX-V: SVA) (OTCQB: SEOVF) (FSE: PSH), a clinical-stage regenerative medicine company, is pleased to announce that Mr. David Swetlow, CPA, CA, has joined Sernova as Chief Financial Officer.

Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced that it will release its third quarter 2019 financial results on Tuesday, Nov. 5 before the open of the U.S. financial markets.

IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in veterinary diagnostics, veterinary practice software and water microbiology testing, today announced that Jonathan Ayers is stepping down as Chairman and a member of the IDEXX management team, effective November 1, 2019.

After a lengthy national search, Unity Health Care is pleased to announce the hiring of Jessica Henderson Boyd, MD, as its new Chief Medical Officer effective November 18, 2019.

Compass Therapeutics, a clinical-stage biotechnology company focused on drugging the human immune synapse to treat human diseases, today announced two upcoming poster presentations at the Society for Immunotherapy of Cancer (SITC) 2019 Annual Meeting, which is being held November 6-10 in National Harbor, MD.

PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing and commercializing regenerative tissue products and biomaterials, today announced that it will report calendar third quarter 2019 financial results by press release on Tuesday, November 12, 2019 at approximately 4:00 p.m. Eastern Time.

The wound irrigation solution market size is expected to post a CAGR of over 3% during the period 2019-2023, according to the latest market research report by Technavio.